ClinicalTrials.gg
CompletedNCT00160654Updated Aug 19, 2020Results posted

Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy

A Phase 4 interventional study of Levetiracetam in Epilepsy, Partial, sponsored by UCB Pharma. Completed at 29 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-19.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Nov 2003, registered Sep 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
251
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing levetiracetam in Epilepsies, Partial — none open to participants now, none under way, none of them phase 3. Levetiracetam · Epilepsies, Partial.

Enrollment
7th of 18
251 · median 173
Started
2003
with 1 other
Phase 4
7 of 18
none open now
Registered
5th of 18
by date
Lead sponsor
10 of 18
UCB Pharma

Among the 18 studies testing levetiracetam in Epilepsies, Partial, this one is the 7th largest by enrollment, is one of 2 that started in 2003, is one of 7 in phase 4, and was the 5th registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

None of the 18 studies testing levetiracetam in Epilepsies, Partial is open now. The open studies under Epilepsies, Partial, anywhere →

About levetiracetam

Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing levetiracetam in Epilepsies, Partial as a file.
02

Study summary

Community based study assessing safety and efficacy of levetiracetam in partial onset seizures.

The optimal dose in daily clinical practice will be used.

03

Conditions studied

  • Epilepsy, Partial

Keywords

  • Epilepsy
  • Partial Onset Seizures
  • Keppra
  • Levetiracetam
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with epilepsy experiencing partial seizures, whether or not secondarily generalized.
  • Subjects must present between 3 and 42 partial seizures over the three months prior to protocol Visit 1.
  • Use of one (1), but no more than two (2) concomitant marketed antiepileptic drugs (AEDs) at the time of trial entry.

Exclusion criteria

Exclusion Criteria:

  • Subjects on vigabatrin, whose visual field has not been assessed as per recommendation of the manufacturer, i.e. every 6 months.
  • Presence of known pseudoseizures within the last year.
  • Presence of progressive cerebral disease, any other progressively degenerative neurological disease, or any cerebral tumors.
  • Uncountable seizures (clusters) or history of convulsive status epilepticus within the last five years.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
251 participants (actual)

Study arms

  • Experimental
    Levetiracetam

    Subjects received open-label Levetiracetam.

    Drug: Levetiracetam

Interventions

  • * Pharmaceutical form: oral tablets * Concentration: 500 mg * Route of administration: Oral use

    Also known as: Keppra

06

What researchers measure

Primary outcomes

  1. Number of Patients With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.

    Time frame: From Baseline until Safety visit (two weeks after last dose; up to Week 18)

Secondary outcomes

  1. Percentage Change From Historical Baseline in Partial (Type I) Seizure Frequency Per Week Over the Treatment Period

    Percentage change from baseline in partial (Type I) seizure frequency over the treatment period standardized to 1 week period. Type I Partial (focal, local) seizure frequency per week will be derived from the seizure count information recorded on the daily record card (e.g. date, number, type of epileptic seizures) and is defined as the number of seizures standardized to a 1 week period. A negative value in percent change from historical baseline indicates a decrease in partial (type I) seizure frequency from historical baseline.

    Time frame: Week 16, compared to Baseline

  2. Percentage Change From Historical Baseline in Total (Type I+II+III) Seizure Frequency Per Week Over the Treatment Period

    Percentage change from baseline in total (type I+II+III) seizure frequency over the treatment period standardized to 1 week period. Types I+II+III seizure frequency (Type I: Partial (focal, local), Type II: Generalized (convulsive or non-convulsive), Type III: Unclassified) per week will be derived from the seizure count information recorded on the daily record card (e.g. date, number, type of epileptic seizures) and is defined as the number of seizures standardized to a 1 week period. A negative value in percent change from historical baseline indicates a decrease in total (type I+II+III) seizure frequency from historical baseline.

    Time frame: Week 16, compared to Baseline

  3. Percentage of Participants With 50% Response in Seizure Frequency Per Week at Week 16

    50% response in seizure frequency per Week is defined as \>=50% reduction in seizure frequency from Baseline. Types I+II+III seizure frequency (Type I: Partial (focal, local), Type II: Generalized (convulsive or non-convulsive), Type III: Unclassified) per week will be derived from the seizure count information recorded on the daily record card (e.g. date, number, type of epileptic seizures) and is defined as the number of seizures standardized to a 1 week period.

    Time frame: Week 16, compared to Baseline

  4. Percentage of Participants With 100% Response in Seizure Frequency Per Week at Week 16

    100% response in seizure frequency per Week is defined as 100% reduction in seizure frequency from Baseline. Types I+II+III seizure frequency (Type I: Partial (focal, local), Type II: Generalized (convulsive or non-convulsive), Type III: Unclassified) per week will be derived from the seizure count information recorded on the daily record card (e.g. date, number, type of epileptic seizures) and is defined as the number of seizures standardized to a 1 week period.

    Time frame: Week 16, compared to Baseline

  5. Percentage of Patients With Categorized Change From Baseline in Severity of Illness

    The overall change in the severity of the subject's illness, compared to the subject's condition prior to the levetiracetam intake, was assessed by the Investigator using Investigator's Global Evaluation Scale (IGS). Categories are as following: Marked improvement; Moderate improvement; Slight improvement; No change; Slight worsening; Moderate worsening; Marked worsening.

    Time frame: Baseline, Week 16

  6. Retention Rate at Week 16

    Retention rate, defined as the number of subjects who were still on levetiracetam at Visit 5 (Week 16) or on the day before divided by the number of subjects in the ITT population.

    Time frame: Week 16

07

Results

Posted Aug 19, 2020

Participant flow

The study started to enroll patients in November 2003 and concluded in May 2006.

Participant flow — Overall Study
MilestoneLevetiracetam
Started251
Completed218
Not completed33
Withdrew: Adverse event14
Withdrew: Lack of efficacy4
Withdrew: Lost to follow-up2
Withdrew: Intake of expired drug7
Withdrew: Psychological trauma1
Withdrew: Sponsor decision1
Withdrew: Patient met exclusion criteria1
Withdrew: Patient decision1
Withdrew: Poor compliance, dilantin toxicity1
Withdrew: Met exclusion criteria1

Outcome measures

PrimaryNumber of Patients With Adverse Events (AEs)

An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.

Time frame:
From Baseline until Safety visit (two weeks after last dose; up to Week 18)
Reported as:
Number · Participants
Number of Patients With Adverse Events (AEs)
ParticipantsLevetiracetam
Number of Patients With Adverse Events (AEs)184
SecondaryPercentage Change From Historical Baseline in Partial (Type I) Seizure Frequency Per Week Over the Treatment Period

Percentage change from baseline in partial (Type I) seizure frequency over the treatment period standardized to 1 week period. Type I Partial (focal, local) seizure frequency per week will be derived from the seizure count information recorded on the daily record card (e.g. date, number, type of epileptic seizures) and is defined as the number of seizures standardized to a 1 week period. A negative value in percent change from historical baseline indicates a decrease in partial (type I) seizure frequency from historical baseline.

Time frame:
Week 16, compared to Baseline
Reported as:
Median · percentage changes
Percentage Change From Historical Baseline in Partial (Type I) Seizure Frequency Per Week Over the Treatment Period
percentage changesLevetiracetam
Percentage Change From Historical Baseline in Partial (Type I) Seizure Frequency Per Week Over the Treatment Period-48.34 (-89.96 to 6.19)
SecondaryPercentage Change From Historical Baseline in Total (Type I+II+III) Seizure Frequency Per Week Over the Treatment Period

Percentage change from baseline in total (type I+II+III) seizure frequency over the treatment period standardized to 1 week period. Types I+II+III seizure frequency (Type I: Partial (focal, local), Type II: Generalized (convulsive or non-convulsive), Type III: Unclassified) per week will be derived from the seizure count information recorded on the daily record card (e.g. date, number, type of epileptic seizures) and is defined as the number of seizures standardized to a 1 week period. A negative value in percent change from historical baseline indicates a decrease in total (type I+II+III) seizure frequency from historical baseline.

Time frame:
Week 16, compared to Baseline
Reported as:
Median · percentage changes
Percentage Change From Historical Baseline in Total (Type I+II+III) Seizure Frequency Per Week Over the Treatment Period
percentage changesLevetiracetam
Percentage Change From Historical Baseline in Total (Type I+II+III) Seizure Frequency Per Week Over the Treatment Period-46.43 (-89.29 to 5.88)
SecondaryPercentage of Participants With 50% Response in Seizure Frequency Per Week at Week 16

50% response in seizure frequency per Week is defined as \>=50% reduction in seizure frequency from Baseline. Types I+II+III seizure frequency (Type I: Partial (focal, local), Type II: Generalized (convulsive or non-convulsive), Type III: Unclassified) per week will be derived from the seizure count information recorded on the daily record card (e.g. date, number, type of epileptic seizures) and is defined as the number of seizures standardized to a 1 week period.

Time frame:
Week 16, compared to Baseline
Reported as:
Number · percentage of participants
Percentage of Participants With 50% Response in Seizure Frequency Per Week at Week 16
percentage of participantsLevetiracetam
Partial (Type I) seizures47.7
Total (type I+II+III) seizures48.1
SecondaryPercentage of Participants With 100% Response in Seizure Frequency Per Week at Week 16

100% response in seizure frequency per Week is defined as 100% reduction in seizure frequency from Baseline. Types I+II+III seizure frequency (Type I: Partial (focal, local), Type II: Generalized (convulsive or non-convulsive), Type III: Unclassified) per week will be derived from the seizure count information recorded on the daily record card (e.g. date, number, type of epileptic seizures) and is defined as the number of seizures standardized to a 1 week period.

Time frame:
Week 16, compared to Baseline
Reported as:
Number · percentage of participants
Percentage of Participants With 100% Response in Seizure Frequency Per Week at Week 16
percentage of participantsLevetiracetam
Partial (Type I) seizures20.2
Total (type I+II+III) seizures20.2
SecondaryPercentage of Patients With Categorized Change From Baseline in Severity of Illness

The overall change in the severity of the subject's illness, compared to the subject's condition prior to the levetiracetam intake, was assessed by the Investigator using Investigator's Global Evaluation Scale (IGS). Categories are as following: Marked improvement; Moderate improvement; Slight improvement; No change; Slight worsening; Moderate worsening; Marked worsening.

Time frame:
Baseline, Week 16
Reported as:
Number · percentage of participants
Percentage of Patients With Categorized Change From Baseline in Severity of Illness
percentage of participantsLevetiracetam
Marked improvement34.1
Moderate improvement25.3
Slight improvement16.5
No change17.7
Slight worsening3.2
Moderate worsening2.8
Marked worsening0.4
SecondaryRetention Rate at Week 16

Retention rate, defined as the number of subjects who were still on levetiracetam at Visit 5 (Week 16) or on the day before divided by the number of subjects in the ITT population.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Retention Rate at Week 16
percentage of participantsLevetiracetam
Retention Rate at Week 1685.3

Adverse events

Collected over Adverse events were collected from Visit 2 (week 2) until Safety Visit (up to 2 weeks after the last dose, up to 16 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Levetiracetam—15/251 (6%)136/251 (54.2%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventLevetiracetam
ConvulsionNervous system disorders4/251
DizzinessNervous system disorders2/251
Grand mal convulsionNervous system disorders2/251
BicytopeniaBlood and lymphatic system disorders1/251
Adverse drug reactionGeneral disorders1/251
Dengue feverInfections and infestations1/251
Thermal burnInjury, poisoning and procedural complications1/251
Coordination abnormalNervous system disorders1/251
Depressed level of consciousnessNervous system disorders1/251
LethargyNervous system disorders1/251
Most frequent other events
Most frequent other events
EventLevetiracetam
SomnolenceNervous system disorders75/251
DizzinessNervous system disorders36/251
HeadacheNervous system disorders16/251
FatigueGeneral disorders15/251
SedationNervous system disorders15/251
NauseaGastrointestinal disorders14/251

Baseline characteristics

Baseline characteristics refer to the Intend-to-treat (ITT) Set.

Age, Categorical
Age, Categorical(Participants)Levetiracetam
<=18 years10
Between 18 and 65 years240
>=65 years1
Age, Continuous
Age, Continuous(years)Levetiracetam
Mean34.42 ± 11.21
Sex: Female, Male
Sex: Female, Male(Participants)Levetiracetam
Female137
Male114
08

Study locations

29 sites
  • N01036 808
    Hong Kong, Hong Kong
  • N01036 842
    Hong Kong, Hong Kong
  • N01036 815
    Kwun Tong, Hong Kong
  • N01036 811
    Kuala Lumpur, Malaysia
  • N01036 812
    Kuala Lumpur, Malaysia
  • N01036 813
    Kuala Lumpur, Malaysia
  • N01036 830
    Manila, Philippines
  • N01036 831
    Manila, Philippines
  • N01036 829
    Quezon, Philippines
  • N01036 804
    Singapore, Singapore
  • N01036 806
    Singapore, Singapore
  • N01036 807
    Singapore, Singapore
  • N01036 828
    Changhua, Taiwan
  • N01036 827
    Hualien City, Taiwan
  • N01036 825
    Kaohsiung City, Taiwan
  • N01036 834
    Kaohsiung, Taiwan
  • N01036 835
    Kaohsiung, Taiwan
  • N01036 823
    Taichung city, Taiwan
  • N01036 817
    Taichung, Taiwan
  • N01036 818
    Tainan, Taiwan
  • N01036 819
    Taipei, Taiwan
  • N01036 820
    Taipei, Taiwan
  • N01036 821
    Taipei, Taiwan
  • N01036 822
    Taoyuan, Taiwan
  • N01036 809
    Bangkok, Thailand
  • N01036 840
    Bangkok, Thailand
  • N01036 841
    Bangkok, Thailand
  • N01036 839
    Chiang Mai, Thailand
  • N01036 810
    Khon Kaen, Thailand
09

References and documents

Publications

  • Kwan P, Lim SH, Chinvarun Y, Cabral-Lim L, Aziz ZA, Lo YK, Tonner F, Beh K, Edrich P; N01036 (SKATE II) Investigator Group. Efficacy and safety of levetiracetam as adjunctive therapy in adult patients with uncontrolled partial epilepsy: the Asia SKATE II Study. Epilepsy Behav. 2010 May;18(1-2):100-5. doi: 10.1016/j.yebeh.2010.03.016. Epub 2010 May 11. PubMed 20462804 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2003 to primary completion in Dec 2006, 36 months.

Results were first posted in Aug 2020, 13 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2005
First posted
Sep 12, 2005
StartActual
Nov 24, 2003
Primary completionActual
Dec 12, 2006
CompletionActual
Dec 12, 2006
Results first posted
Aug 19, 2020
Last update
Aug 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00160654
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Sep 12, 2005
Start date
Nov 24, 2003
Primary completion
Dec 12, 2006
Completion
Dec 12, 2006
Results posted
Aug 19, 2020
Last update
Aug 19, 2020

Study contacts

UCB Cares
study director · UCB (+1 844 599 2273)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion